Chronic Cellular NAD Depletion Activates a Viral Infection-Like Interferon Response Through Mitochondrial DNA Leakage
- PMID: 40519092
- PMCID: PMC12419838
- DOI: 10.1111/acel.70135
Chronic Cellular NAD Depletion Activates a Viral Infection-Like Interferon Response Through Mitochondrial DNA Leakage
Abstract
Nicotinamide adenine dinucleotide (NAD) is a key coenzyme involved in energy metabolism, DNA repair, and cellular signaling. While the effects of acute NAD depletion have been better characterized, the consequences of chronic NAD deficiency remain unclear. Here, we investigated the impact of chronic NAD depletion in cultured cells by removing the availability of nicotinamide (NAM), a key precursor for NAD synthesis, from the culture media. In NIH3T3 fibroblasts, NAM depletion caused a dramatic drop in intracellular NAD levels within 2 days. Remarkably, the cells remained viable even after 7-14 days of NAM depletion, despite NAD+ levels falling to less than 10% of control conditions. This chronic NAD depletion led to distinct metabolic alterations. Mitochondrial basal respiration remained unchanged, but cells exhibited reduced spare respiratory and maximal capacities, along with significantly impaired glycolysis. Notably, NAD depletion triggered an interferon-dependent inflammatory response, resembling viral infections. This was driven by cytosolic leakage of mitochondrial DNA (mtDNA) through voltage-dependent anion channel 1 (VDAC1), which activated the cGAS-STING signaling pathway. Inhibition of VDAC oligomerization with VBIT-4, STING signaling with H-151, or mtDNA depletion blocked the upregulation of interferon genes induced by NAM depletion. Similar interferon responses triggered by NAD depletion were observed in IMR90 human fibroblasts and HS5 stromal cells. Our findings reveal a novel link between chronic NAD deficiency, VDAC-mediated mtDNA release to the cytoplasm, and the activation of the inflammatory response, providing new insight into how NAD decline affects cellular metabolic and inflammatory processes.
© 2025 The Author(s). Aging Cell published by Anatomical Society and John Wiley & Sons Ltd.
Conflict of interest statement
E.N.C. holds a patent on the use of CD38 inhibitors for metabolic diseases that is licensed by Elysium Health. E.N.C. is a consultant for TeneoBio, Calico, Mitobridge, and Cytokinetics. E.N.C. is on the advisory board of Eolo Pharma. E.N.C. owns stocks in TeneoBio. Research in the Chini laboratory has been conducted in compliance with the Mayo Clinic conflicts of interest policies. The other authors declare no competing interests.
Figures







References
-
- Alaee, M. , Khaghani S., Behroozfar K., Hesari Z., Ghorbanhosseini S. S., and Nourbakhsh M.. 2017. “Inhibition of Nicotinamide Phosphoribosyltransferase Induces Apoptosis in Estrogen Receptor‐Positive MCF‐7 Breast Cancer Cells.” Journal of Breast Cancer 20, no. 1: 20–26. 10.4048/jbc.2017.20.1.20. - DOI - PMC - PubMed
-
- Basse, A. L. , Nielsen K. N., Karavaeva I., et al. 2023. “NAMPT‐Dependent NAD+ Biosynthesis Controls Circadian Metabolism in a Tissue‐Specific Manner.” Proceedings of the National Academy of Sciences of the United States of America 120, no. 14: e2220102120. 10.1073/pnas.2220102120. - DOI - PMC - PubMed